Published in final edited form as:

Biol Psychiatry. 2010 June 15; 67(12): 1212–1216. doi:10.1016/j.biopsych.2010.01.026.

A novel transgenic mouse for gene-targeting within cells that express corticotropin-releasing factor

Elizabeth I. Martin, PhD^{*},

Peptide Biology Laboratory, The Salk Institute, 10010 N. Torrey Pines Road, La Jolla, CA 92037, emartin@salk.edu, Office: 858-453-4100, ext. 1510, Fax: 858-558-8763

Kerry J. Ressler, MD, PhD^{*},

Investigator, Howard Hughes Medical Institute, Associate Professor, Department of Psychiatry and Behavioral Sciences, Yerkes Research Center, Emory University, Mailing address:, 954 Gatewood Dr, Atlanta, GA 30329, kressle@emory.edu, (ph) 404-727-7739, (fax) 404-727-8070

Aaron M. Jasnow, PhD,

Emory University, Yerkes Primate Research Center, NSB 5224, 954 Gatewood RD NE, Atlanta, GA 30329, ajasnow@emory.edu, Tel: 404-727-7997

Joanna Dabrowska, Ph.D.,

Center for Behavioral Neuroscience, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, jdabrow@emory.edu, 404-712-3592

Rimi Hazra, PhD,

Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, rhazra@emory.edu, 404-712-3592

Donald G. Rainnie,

Department of Psychiatry and Behavioral Sciences, Yerkes Research Center, Emory University, Mailing address: 954 Gatewood Dr, Atlanta, GA 30329, drainnie@emory.edu

Charles B. Nemeroff, MD, PhD, and

© 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Corresponding Author: Elizabeth I. Martin, PhD, Peptide Biology Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Rd., La Jolla, CA 92037, (404)3949147 emartin@salk.edu.

^{*}These authors contributed equally.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

FINANCIAL DISCLOSURES:

Dr. Ressler has received awards and/or funding support from Lundbeck, Burroughs Wellcome Foundation, Pfizer, NARSAD, NIMH, NIDA, and has a consulting agreement with Tikvah Therapeutics for NMDA-based therapeutics.
Dr Rainnie has received research grants from NIMH, NARSAD and the Whitehall Foundation. Grant #'s MH069852 and MH072908
Dr. Nemeroff currently serves on the scientific advisory boards of American Foundation for Suicide Prevention (AFSP); AstraZeneca; NARSAD; and PharmaNeuroboost. He holds stock/equity in Corcept; Revaax; NovaDel Pharma; CeNeRx, and PharmaNeuroboost.
He is on the board of directors of the AFSP; NovaDel Pharma, and Mt. Cook Pharma, Inc. Dr. Nemeroff holds a patent on the method and devices for transdermal delivery of lithium (US 6,375,990 B1) and the method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April, 2001). In the past year, he also served on the Scientific Advisory Board for Forest Laboratories, received grant support from NIMH, NARSAD and AFSP.
Dr. Owens has research Grants from NIH, Eli Lilly, Pfizer, GlaxoSmithKline, Lundbeck, Cyberonics, Ortho-McNeil Janssen, AstraZeneca, Dainippon Sumitomo. He is a consultant with H. Lundbeck A/S, and Honorarium with Eli Lilly. Dr. Owens has a patent entitled "A method to estimate transporter occupancy."
Drs. Martin, Jasnow, Hazra and Dabrowska reported no biomedical financial interests or potential conflicts of interest.

Leonard M. Miller Professor and Chairman, Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Clinical Research Building, 1120 NW 14th Street, Room 1455 (D-21), Miami, Florida 33136, Off: 305-243-3740, Fax: 305-243-1619, cnemeroff@med.miami.edu

Michael J. Owens

Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University, Mailing Address: Woodruff Memorial Research Building, Suite 4000, 101 Woodruff Circle, Atlanta, GA 30322, mowens@emory.edu

Abstract

Corticotropin-releasing factor (CRF) orchestrates the mammalian endocrine, autonomic, and behavioral stress response and has been implicated in the pathophysiology of illnesses ranging from irritable bowel syndrome to mood and anxiety disorders. CRF is produced and released from a variety of cell types, making it difficult to distinguish the specific role of CRF from other neurotransmitters with which it colocalizes. To clarify the basic biology of the CRF neuron, we must be able to manipulate selectively CRFergic cells. Here we describe a novel transgenic mouse using 3.0Kb of the CRF promoter to drive expression of Cre-recombinase (CRFp3.0Cre). Crossing CRFp3.0Cre with a fluorescent reporter strain results in Cre-dependent GFP expression within CRF-producing cells. Thus CRF cells can be identified for single-cell PCR and electrophysiological procedures. Furthermore, the CRFp3.0Cre transgenic can be combined with other available mouse strains containing a “floxed” gene of interest to allow unparalleled detailed analysis of the CRF system.

INTRODUCTION

CRF, a 41 amino acid peptide, was discovered in 1981 by Vale and colleagues for its role in activating the hypothalamic-pituitary-adrenal (HPA) axis, a primary endocrine reaction to perceived threat. CRF has since been recognized as a key coordinator of autonomic and behavioral stress-responsivity via extrahypothalamic actions in the brainstem and limbic system, respectively [1–5]. Though critical in the face of real threat, overactive or inappropriate activation of CRF and the stress-response systems it coordinates can have severe consequences for mental and physical health [6–9].

Despite its importance in adaptive and pathological stress responsivity, the innerworkings of CRFergic neurons are not well understood. CRF is produced in a variety of cell types including neurons and glia [10] and is colocalized with numerous neurotransmitters and neuropeptides [11–15]; this heterogeneity complicates efforts to clarify region and cell-type specific influences of CRF. Here we describe the development of a novel transgenic mouse in which CRFergic cells can be identified and manipulated apart from neighboring cells.

Using our previously outlined method of screening promoters for cell-type-specific expression [16], we amplified 3.0Kb upstream of the ATG start site for the CRF coding sequence. This 3.0Kb promoter, inserted into a lentiviral vector backbone, drives expression of Cre-recombinase (LVCRFp3.0Cre, Figure S1 in Supplement 1). Cre, a 35-kDa enzyme, recognizes 34bp sequences known as “LoxP” sites and excises DNA flanked by LoxP sites (“floxed”) via intrachromosomal recombination [17,18]. The LVCRFp3.0Cre construct was then used to establish a transgenic mouse in which CRF-producing cells also express Cre (CRFp3.0Cre).

Crossing CRFp3.0Cre mice with fluorescent Cre-reporter strains results in expression of green fluorescent protein (GFP), permitting real-time visualization of CRFergic cells for use

in single cell PCR and electrophysiological procedures. Importantly, CRFp3.0Cre mice can also be crossed with available transgenics containing a “floxed” gene; such dual transgenics will improve by leaps and bounds our understanding of interactions between CRF and other signaling molecules within CRFergic cells under normal and pathological conditions.

METHODS

CRFp3.0Cre Vector

3.0Kb of the CRF promoter was PCR amplified and topo-cloned into pCR2.1-topo, (Invitrogen, Carlsbad, CA). A lentivirus backbone, pCMVGFPdNhe [19] (Inder Verma, Salk Institute) was digested to remove the CMVGFP sequence. The linearized backbone was ligated to the 3.0Kb CRF promoter and to the Cre coding sequence, using T4 DNA ligase (New England Biolabs.)

CRFp3.0Cre Mouse

After preliminary tests of promoter functionality and specificity (Figure S2 in Supplement 1), the LVCRFp3.0Cre construct was linearized, purified by electroelution, and diluted to 2ng/μl for pronuclear microinjection into FVB mouse cells by the Emory University Transgenic Core Facility. F1 offspring, PCR positive for CRFp3.0Cre, were crossed with one of three Cre-reporter strains, denoted below as CRFp3.0Cre^{LacZ}, CRFp3.0Cre^{GFP}, and CRFp3.0Cre^{mT/mG}. Procedures are approved by Emory University's IACUC.

In situ Hybridization

CRFp3.0Cre mice were sacrificed with CO₂, brains were fresh-frozen and sectioned at 20μm on a cryostat. *In situ* hybridization for Cre and CRF transcripts were performed on serial slides using ³⁵S-UTP labeled riboprobes as described previously [20].

X-Gal Staining

CRFp3.0Cre mice were crossed with a strain containing a Floxed-stop-LacZ construct in the Rosa26 locus (Rosa LacZ, Jackson Laboratories). CRFp3.0Cre^{LacZ} offspring were sacrificed with chloral hydrate and perfused. 20μm-thick brain sections were collected in series on SuperFrostPlus slides (Fisher Scientific). Slides were rinsed in PBS then incubated overnight in X-gal solution. At least 10 different CRFp3.0Cre^{LacZ} mice were examined; their expression patterns are represented in Figure 1.

Immunohistochemistry

CRFp3.0Cre was crossed with a fluorescent Cre-reporter strain containing cytoplasmic EGFP downstream of a floxed-stop construct (CAG-Bgeo/GFP, Jackson Laboratories # 003920). Immunohistochemistry for CRF peptide was performed on offspring from these matings (CRFp3.0Cre^{GFP}) to verify colocalization of Cre enzymatic activity with CRF peptide.

Electrophysiology

CRFp3.0Cre^{GFP} mice were decapitated under isoflurane anesthesia (Abbott Laboratories, North Chicago, IL). Brains were placed in kynurenic acid-based artificial cerebrospinal fluid (ACSF_{KA}) [21–23]. 350μm coronal slices were cut, hemisected, transferred to ACSF_{KA}, and gassed with a 95/5% oxygen/carbon dioxide mixture for 1hr before being placed in oxygenated control ACSF; recordings began 30min later.

Single-cell RT-PCR

Cytoplasm was aspirated from 25 GFP⁺ and 8 GFP[−] cells. For each cell, cytoplasm was expelled into a microcentrifuge tube containing reverse transcription (RT) cocktail (Applied Biosystems, Foster City, CA). RT product was amplified in triplicate as previously described [24], and screened for 18S rRNA. Only those cells positive for 18S rRNA were subjected to amplification with primers for CRF.

Specific methods for each of these procedures are included in Supplement 1.

RESULTS and DISCUSSION

The paramount importance of CRF in the normal and pathological response to a threatening situation is clear, yet the inner workings of CRF-containing circuits remain poorly understood. Achieving restricted transgene expression within CRF-expressing cells in this novel CRFp3.0Cre mouse strain has the potential to rapidly expand our understanding of CRF regulation in a region-specific manner and perhaps contribute to the identification of relevant targets within selective CRF circuits.

As the first step in characterizing this novel strain, expression of CRF transcript was compared with that of Cre in serial slices from F2 and F3-generation CRFp3.0Cre mice. *In situ* hybridization revealed a high degree of congruence in regional expression of these two transcripts in serial coronal slices (n = 9 mice, representative images are shown in Figures 1A–1D).

As a second step in characterizing CRFp3.0Cre mice, Cre enzymatic activity was assessed in CRFp3.0Cre mice crossed with the Rosa-LacZ strain (CRFp3.0Cre^{LacZ}). In these dual transgenics, the pattern of LacZ expression matched that of CRF within the CeA (Figure 1E), the Bed Nucleus of the Stria Terminalis (Figure 1E), and the paraventricular nucleus of the hypothalamus (PVN) (Figures 1F–G). A small amount of LacZ⁺ cells were scattered within the cortex, consistent with the pattern of cortical CRF. There was no other concentrated LacZ expression throughout the remainder of the brain and brainstem.

Functional Cre enzymatic activity was also assessed by crossing CRFp3.0Cre mice with a Cre-reporter strain containing a membrane bound EGFP (CRFp3.0Cre^{mT/mG}, Figure S4 in Supplement 1), as well as a reporter strain with cytoplasmic EGFP downstream of a floxed-stop construct (CRFp3.0Cre^{GFP}). Immunohistochemistry for CRF was performed on 6 slices from 4 CRFp3.0Cre^{GFP} subjects using a red fluorophore-tagged secondary antibody and compared with endogenous (Cre-mediated) GFP expression. At the cellular level, CRF-like immunoreactivity colocalized with Cre-dependent GFP expression, providing firm support that the 3.0Kb CRF ‘mini-promoter’ targets transgene expression to CRFergic cells (Figure 2). Potential explanations for the occasional CRF⁺/GFP[−] or CRF[−]/GFP⁺ cell are discussed below.

In tissue from CRFp3.0Cre^{GFP} transgenics, GFP[−] expressing neurons have been visualized in real time and targeted for electrophysiological recordings. Acute brain slices were prepared and recordings were obtained from visually identified GFP⁺ (putative CRFergic) CeA neurons in CRFp3.0Cre^{GFP} subjects (Figure 3). Multiple GFP⁺ cells have now been recorded from over 20 different CRFp3.0Cre^{GFP} mice; Figure 3A shows a representative trace. These data demonstrate the viability of cell-type-selective promoters to label and characterize electrophysiological properties of a sub-population of neurons.

Given the limited quantitative nature of immunohistochemistry, single-cell PCR was our primary method to determine the sensitivity and specificity of the CRFp3.0Cre^{GFP}

transgenic line. Of 8 GFP[−] cells, none contained CRF mRNA, suggesting very high specificity of GFP expression for CRF-expressing cells; >90% of GFP[−] cells are also CRF[−]. Of 25 GFP⁺ cells, 21 were also CRF⁺, suggesting that approximately 85% of the GFP⁺ cells contain detectable levels of CRF transcript (Figure 3D–E).

With all promoter-driven reporter transgenic mice, the main concern is specificity of reporter expression. In the immunohistochemistry experiment, at least one cell with CRF-like immunoreactivity lacks concurrent expression of GFP (arrowhead in Figure 2). This CRF⁺/GFP[−] cell may have very recently begun to express CRF and not had time to produce detectable levels of GFP. In the RT-PCR experiment, lack of CRF expression in 4 of the GFP⁺ cells can be explained by the sensitivity and irreversibility of Cre-mediated DNA excision; once Cre-mediated excision has occurred, GFP expression is not dependent on continued activation of the CRF promoter; expression of the GFP construct will continue even if the cell no longer expresses CRF. The detection limits of the single cell RT-PCR approach could also contribute to the finding of GFP⁺/CRF[−] cells.

To summarize, Cre expression in this novel strain exhibits extremely high regional specificity and 85–90% sensitivity and specificity for CRFergic cells. This is true even within the CeA, a region of dense CRF expression. Thus, we are confident that the CRFp3.0Cre mouse reliably produces Cre within CRFergic cells. Ongoing experiments using CRFp3.0Cre mice crossed with fluorescent Cre-reporters as well as other “floxed” transgenics continue to support this conjecture.

The utility of the CRFp3.0Cre strain is two-fold: **1)** When crossed with a Cre-reporter strain, CRF cells are easily identifiable and distinguishable from neighboring cells for the purposes of single cell mRNA isolation and RT-PCR, laser capture, fluorescence activated cell sorting and intracellular recording; **2)** Crossing CRFp3.0Cre with extant mouse strains containing “floxed” gene constructs will extend knowledge of interactions between CRF and other signaling molecules. These properties will be employed to clarify basic cellular biology of CRF-producing neurons and stress-induced alterations in CRFergic cells which may contribute to the pathophysiological conditions attributed to CRF overexpression.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Thank you to the following funding institutions and agencies: NIH MH-42088, MH079667A, MH-541380, MH-77083, MH-69056, MH-58922, MH-39415, DA019624, and RR-00039; Burroughs Wellcome Fund.

WORKS CITED

1. Vale W, et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. *Science* 1981;213(4514):1394–1397. [PubMed: 6267699]
2. Melia KR, Duman RS. Involvement of corticotropin-releasing factor in chronic stress regulation of the brain noradrenergic system. *Natl Acad Sci U S A* 1991;88(19):8382–8386.
3. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? *Brain Res Brain Res Rev* 1990;15(2):71–100. [PubMed: 1980834]
4. Stout SC, et al. Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. *Eur J Pharmacol* 2000;401(1):39–46. [PubMed: 10915835]
5. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. *Pharmacol Rev* 1991;43(4):425–473. [PubMed: 1775506]

6. Tache Y, Brunnhuber S. From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases. *Ann N Y Acad Sci* 2008;1148:29–41. [PubMed: 19120089]
7. Arborelius L, et al. The role of corticotropin-releasing factor in depression and anxiety disorders. *J Endocrinol* 1999;160(1):1–12. [PubMed: 9854171]
8. Mitchell AJ. The role of corticotropin releasing factor in depressive illness: a critical review. *Neurosci Biobehav Rev* 1998;22(5):635–651. [PubMed: 9662725]
9. Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. *Horm Behav* 2006;50(4):550–561. [PubMed: 16870185]
10. Kapcala LP, Dicke JA. Brain corticotropin-releasing hormone receptors on neurons and astrocytes. *Brain Res* 1992;589(1):143–148. [PubMed: 1330205]
11. Sawchenko PE, Swanson LW. Localization, colocalization, and plasticity of corticotropin-releasing factor immunoreactivity in rat brain. *Fed Proc* 1985;44(1 Pt 2):221–227. [PubMed: 2981743]
12. Honkaniemi J, et al. Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. *Neuroendocrinology* 1992;55(4):451–459. [PubMed: 1373477]
13. Smialowska M, Wieronska JM, Wedzony K. A search for colocalization of mglu1 receptors with CRF or NPY in the rat brain amygdala. *Folia Histochem Cytobiol* 2002;40(2):153–154. [PubMed: 12056621]
14. Hisano S, et al. Intragranular colocalization of arginine vasopressin and methionine-enkephalin-octapeptide in CRF-axons in the rat median eminence. *Cell Tissue Res* 1987;249(3):497–507. [PubMed: 3499227]
15. Palkovits M. Stress-induced expression of co-localized neuropeptides in hypothalamic and amygdaloid neurons. *Eur J Pharmacol* 2000;405(1–3):161–166. [PubMed: 11033323]
16. Chhatwal JP, et al. Identification of cell-type-specific promoters within the brain using lentiviral vectors. *Gene Ther* 2007;14(7):575–583. [PubMed: 17235291]
17. Wilson TJ, Kola I. The LoxP/CRE system and genome modification. *Methods Mol Biol* 2001;158:83–94. [PubMed: 11236673]
18. Lewandoski M. Conditional control of gene expression in the mouse. *Nat Rev Genet* 2001;2(10):743–755. [PubMed: 11584291]
19. Tiscornia G, et al. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. *Proc Natl Acad Sci U S A* 2003;100(4):1844–1848. [PubMed: 12552109]
20. Ressler KJ, et al. Regulation of synaptic plasticity genes during consolidation of fear conditioning. *J Neurosci* 2002;22(18):7892–7902. [PubMed: 12223542]
21. Rainnie DG, et al. Physiological and morphological characterization of parvalbumin-containing interneurons of the rat basolateral amygdala. *J Comp Neurol* 2006;498(1):142–161. [PubMed: 16856165]
22. McDonald AJ, et al. Evidence for a perisomatic innervation of parvalbumin-containing interneurons by individual pyramidal cells in the basolateral amygdala. *Brain Res* 2005;1035(1):32–40. [PubMed: 15713274]
23. Rainnie DG, Holmes KH, Shinnick-Gallagher P. Activation of postsynaptic metabotropic glutamate receptors by trans-ACPD hyperpolarizes neurons of the basolateral amygdala. *J Neurosci* 1994;14(11 Pt 2):7208–7220. [PubMed: 7965109]
24. Kurimoto K, et al. An improved single-cell cDNA amplification method for efficient high-density oligonucleotide microarray analysis. *Nucleic Acids Res* 2006;34(5):e42. [PubMed: 16547197]

Figure 1. Cre-recombinase Transcript and Enzymatic Activity Correspond to CRF Transcript Expression

In situ hybridization for CRF (A,C) and Cre-recombinase (B,D) from the CeA (top) and PVN (bottom) of a CRFp3.0Cre mouse. LacZ staining with X-Gal demonstrates functional Cre activity in the CeA (E), BNST (F), and PVN at low (G) and high power (H) of a CRFp3.0Cre^{LacZ} mouse.

Figure 2. Cre-Dependent Expression of GFP Colocalizes with CRF Peptide in the CeA
 (A) Endogenous GFP expression in the CeA of a CRFp3.0CreGFP mouse (63x Magnification); (B) Immunohistochemistry for CRF (Abcam, rabbit polyclonal anti-CRF) in a serial section from the same animal; CRF-like immunoreactivity is visualized with AlexaFluor568-tagged secondary antibody. (C) Merged Image. Arrows demonstrate cells with high levels of co-expression of GFP and CRF. The arrowhead demonstrates the occasional cell that is CRF⁺/GFP⁻. The chevron identifies the occasional cell that is CRF⁻/GFP⁺, see text for discussion.

Figure 3. Physiological and Molecular Properties of Visually Identified, PCR-Verified CRFergic Cells

(A) Voltage response of a CRF-containing neuron to transient (750ms) hyperpolarizing and depolarizing current injections. (B) CRF neurons are driven by a continuous input of spontaneous EPSCs. (C) Photomicrograph showing the expression of CRF-driven GFP in the CeA. Arrow indicates neuron illustrated in A and B. Stars indicate GFP- neurons. (D) Single cell RT-PCR demonstrating mRNA expression of CRF aspirated from GFP+ (right lane) but not GFP- (center lane) cells in the CeA. The PCR product for CRF is 394bp; M = 100bp ladder. (E) Quantification of 33 CeA cells aspirated and analyzed with RT-PCR.